ReviewJournal of neurology2008
National MS registries.
Review in Journal of neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.Journal of neurology · 2025Article
- Dietary Inflammatory Score (DIS)'s and Lifestyle Inflammatory Score (LIS)'s Impact on Multiple Sclerosis Severity.Nutrients · 2025Article
- Article
- Demyelinating diseases of the central nervous system registry for patients with traditional Chinese medicine: Rationale and design of a prospective, multicenter, observational study.Frontiers in pharmacology · 2022Article
- Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohort.Therapeutic advances in neurological disorders · 2022Article
- Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry.Scientific reports · 2021Article
- Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System.Frontiers in digital health · 2021Review
- Article
- A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.Frontiers in immunology · 2017Review
- Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.BMC neurology · 2016Review
- Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.Therapeutic advances in neurological disorders · 2016Review
- Telemedicine for Monitoring MS Activity and Progression.Current treatment options in neurology · 2015Article
- The role of information system in multiple sclerosis management.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2014Review
- Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord.Molecular biotechnology · 2014Article
- A comparative study on iMed(©) and European database for multiple sclerosis to propose a common language of multiple sclerosis data elements.Journal of education and health promotion · 2014Article
- Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.Molecular immunology · 2013Article
- Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring.BMC neurology · 2013Article
- Methodology of an International Study of People with Multiple Sclerosis Recruited through Web 2.0 Platforms: Demographics, Lifestyle, and Disease Characteristics.Neurology research international · 2013Article
- Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.Neuroscience letters · 2012Article
- Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Wiener medizinische Wochenschrift (1946) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review gives an overview of national registries that are currently in use for patients with multiple sclerosis (MS). The large-scale registries described herein include the Danish MS Registry, the Norwegian MS Registry, the Swedish MS Registry, the Italian MS Database Network, the North-American NARCOMS Registry, and the German MS Registry. These MS registries are extremely helpful for studying disease characteristics in large populations and monitoring the long-term outcome of disease-modifying therapies. Furthermore, an almost complete ascertainment of cases provides information on the provision of treatments, services and supplies within a given area that may be used to compare different levels of health care within and between these regions. In the long-term, MS registries monitor the health care situation of MS patients over time including the implementation of guidelines relating to care and treatment, measure the improvements that have taken place, and reveal shortages and/or misalignment in health care services. The information gathered herein is not only useful for the long-term follow-up of the individual patient, but also for society as a whole by increasing understanding of and knowledge about MS and allowing national authorities and relevant parties to make informed and relevant decisions about MS.
Indexed as
Identifiers
19300969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.